



Ultomiris in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

RARE DISEASE · PNH / AHUS / GMG / NMOSD

The clinical situation

Ultomiris (ravulizumab-cwvz) is an FDA-approved long-acting complement C5 monoclonal antibody engineered from eculizumab for an every-8-week maintenance interval in PNH, aHUS, generalized myasthenia gravis, and NMOSD. Manufactured by Alexion (AstraZeneca). Weight-based IV dosing; meningococcal vaccination required. Requires 2–8°C cold-chain storage.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating hematologist or nephrologist confirms diagnosis with appropriate laboratory workup and documents weight-based dosing plan; meningococcal vaccination administered.
- 2 Infusion centre confirmed.** A Saudi infusion centre or tertiary hospital (Riyadh, Jeddah, Eastern Province) accepts the case for every-8-week infusions.
- 3 SFDA named-patient application.** Clinical rationale, patient reference, product details, weight-based dose, and cold-chain plan are filed with the Saudi Food & Drug Authority.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner on validated 2–8°C cold-chain.
- 5 Arrival & administration.** The infusion centre receives the dose under temperature-monitored handling; maintenance every 8 weeks.

Indicative economics

Reference US cash-pay range: USD 60,000–80,000 per 8-week maintenance dose (weight-based). Cold-chain logistics, SFDA documentation, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete SFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review. **Logistics.** Cold-chain, temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Ultomiris × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/ultomiris-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team